Induction of TRAIL-mediated apoptosis in GC lines only (p < 0.01)Inhibition of peritoneal metastases, lower tumor weights with Ad/TRAIL-E1 (p < 0.05)Prolonged survival (83 days) compared to control (PBS—46 days) or Ad/CMV-GFP treatment (55 days) (p < 0.01). The gene discussed is TNFSF10; the disease is neoplasm.